StreetInsider.com News Articles

Poxel Publishes Its Turnover for the Second Quarter of 2026 and Announces the Postponement of the Publication of Its 2025 Financial Statements

Thu, 30 Jul 2026 15:30:00 -0400

Consolidated net sales of TWYMEEG® in Japan for the 2nd quarter of 2026 reached 2.9 billion yen (15.5 million euros1), up 32 per cent compared with the 2nd quarter of 2025.
Consolidated net sales of TWYMEEG® in Japan for the 1st half of 2026 reached 5.2 billion yen (28.2 million euros1), up 34 per cent compared with the 1st half of 2025.
Sumitomo Pharma anticipates that net sales of TWYMEEG® will exceed the 10-billion-yen mark in Sumitomo Pharma’s financial year 20262. Upon reaching this milestone, POXEL will receive a contractual bonus of 1 billion yen (5.5 million euros1); the royalty rate

Poxel Publishes Its Turnover for the Second Quarter of 2026 and Announces the Postponement of the Publication of Its 2025 Financial Statements

Thu, 30 Jul 2026 15:30:00 -0400

Consolidated net sales of TWYMEEG® in Japan for the 2nd quarter of 2026 reached 2.9 billion yen (15.5 million euros1), up 32 per cent compared with the 2nd quarter of 2025.

Consolidated net sales of TWYMEEG® in Japan for the 1st half of 2026 reached 5.2 billion yen (28.2 million euros1), up 34 per cent compared with the 1st half of 2025.

Sumitomo Pharma anticipates that net sales of TWYMEEG® will exceed the 10-billion-yen mark in Sumitomo Pharma’s financial year 20262. Upon reaching this milestone, POXEL will receive a contractual bonus of 1 billion yen (5.5 million euros1); the royalty rate

Poxel Publishes Its Turnover for the Second Quarter of 2026 and Announces the Postponement of the Publication of Its 2025 Financial Statements

Thu, 30 Jul 2026 15:30:00 -0400

Consolidated net sales of TWYMEEG® in Japan for the 2nd quarter of 2026 reached 2.9 billion yen (15.5 million euros1), up 32 per cent compared with the 2nd quarter of 2025.

Consolidated net sales of TWYMEEG® in Japan for the 1st half of 2026 reached 5.2 billion yen (28.2 million euros1), up 34 per cent compared with the 1st half of 2025.

Sumitomo Pharma anticipates that net sales of TWYMEEG® will exceed the 10-billion-yen mark in Sumitomo Pharma’s financial year 20262. Upon reaching this milestone, POXEL will receive a contractual bonus of 1 billion yen (5.5 million euros1); the royalty rate

Poxel Publishes Its Turnover for the Second Quarter of 2026 and Announces the Postponement of the Publication of Its 2025 Financial Statements

Thu, 30 Jul 2026 15:30:00 -0400

Consolidated net sales of TWYMEEG® in Japan for the 2nd quarter of 2026 reached 2.9 billion yen (15.5 million euros1), up 32 per cent compared with the 2nd quarter of 2025.

Consolidated net sales of TWYMEEG® in Japan for the 1st half of 2026 reached 5.2 billion yen (28.2 million euros1), up 34 per cent compared with the 1st half of 2025.

Sumitomo Pharma anticipates that net sales of TWYMEEG® will exceed the 10-billion-yen mark in Sumitomo Pharma’s financial year 20262. Upon reaching this milestone, POXEL will receive a contractual bonus of 1 billion yen (5.5 million euros1); the royalty rate

Poxel Publishes Its Turnover for the Second Quarter of 2026 and Announces the Postponement of the Publication of Its 2025 Financial Statements

Thu, 30 Jul 2026 15:30:00 -0400

Consolidated net sales of TWYMEEG® in Japan for the 2nd quarter of 2026 reached 2.9 billion yen (15.5 million euros1), up 32 per cent compared with the 2nd quarter of 2025.

Consolidated net sales of TWYMEEG® in Japan for the 1st half of 2026 reached 5.2 billion yen (28.2 million euros1), up 34 per cent compared with the 1st half of 2025.

Sumitomo Pharma anticipates that net sales of TWYMEEG® will exceed the 10-billion-yen mark in Sumitomo Pharma’s financial year 20262. Upon reaching this milestone, POXEL will receive a contractual bonus of 1 billion yen (5.5 million euros1); the royalty rate

Poxel Publishes Its Turnover for the Second Quarter of 2026 and Announces the Postponement of the Publication of Its 2025 Financial Statements

Thu, 30 Jul 2026 15:30:00 -0400

Consolidated net sales of TWYMEEG® in Japan for the 2nd quarter of 2026 reached 2.9 billion yen (15.5 million euros1), up 32 per cent compared with the 2nd quarter of 2025.

Consolidated net sales of TWYMEEG® in Japan for the 1st half of 2026 reached 5.2 billion yen (28.2 million euros1), up 34 per cent compared with the 1st half of 2025.

Sumitomo Pharma anticipates that net sales of TWYMEEG® will exceed the 10-billion-yen mark in Sumitomo Pharma’s financial year 20262. Upon reaching this milestone, POXEL will receive a contractual bonus of 1 billion yen (5.5 million euros1); the royalty rate

Poxel Publishes Its Turnover for the Second Quarter of 2026 and Announces the Postponement of the Publication of Its 2025 Financial Statements

Thu, 30 Jul 2026 15:30:00 -0400

Consolidated net sales of TWYMEEG® in Japan for the 2nd quarter of 2026 reached 2.9 billion yen (15.5 million euros1), up 32 per cent compared with the 2nd quarter of 2025.

Consolidated net sales of TWYMEEG® in Japan for the 1st half of 2026 reached 5.2 billion yen (28.2 million euros1), up 34 per cent compared with the 1st half of 2025.

Sumitomo Pharma anticipates that net sales of TWYMEEG® will exceed the 10-billion-yen mark in Sumitomo Pharma’s financial year 20262. Upon reaching this milestone, POXEL will receive a contractual bonus of 1 billion yen (5.5 million euros1); the royalty rate

Poxel Publishes Its Turnover for the Second Quarter of 2026 and Announces the Postponement of the Publication of Its 2025 Financial Statements

Thu, 30 Jul 2026 15:30:00 -0400

Consolidated net sales of TWYMEEG® in Japan for the 2nd quarter of 2026 reached 2.9 billion yen (15.5 million euros1), up 32 per cent compared with the 2nd quarter of 2025.

Consolidated net sales of TWYMEEG® in Japan for the 1st half of 2026 reached 5.2 billion yen (28.2 million euros1), up 34 per cent compared with the 1st half of 2025.

Sumitomo Pharma anticipates that net sales of TWYMEEG® will exceed the 10-billion-yen mark in Sumitomo Pharma’s financial year 20262. Upon reaching this milestone, POXEL will receive a contractual bonus of 1 billion yen (5.5 million euros1); the royalty rate

Poxel Publishes Its Turnover for the Second Quarter of 2026 and Announces the Postponement of the Publication of Its 2025 Financial Statements

Thu, 30 Jul 2026 15:30:00 -0400

Consolidated net sales of TWYMEEG® in Japan for the 2nd quarter of 2026 reached 2.9 billion yen (15.5 million euros1), up 32 per cent compared with the 2nd quarter of 2025.

Consolidated net sales of TWYMEEG® in Japan for the 1st half of 2026 reached 5.2 billion yen (28.2 million euros1), up 34 per cent compared with the 1st half of 2025.

Sumitomo Pharma anticipates that net sales of TWYMEEG® will exceed the 10-billion-yen mark in Sumitomo Pharma’s financial year 20262. Upon reaching this milestone, POXEL will receive a contractual bonus of 1 billion yen (5.5 million euros1); the royalty rate

Poxel Publishes Its Turnover for the Second Quarter of 2026 and Announces the Postponement of the Publication of Its 2025 Financial Statements

Thu, 30 Jul 2026 15:30:00 -0400

Consolidated net sales of TWYMEEG® in Japan for the 2nd quarter of 2026 reached 2.9 billion yen (15.5 million euros1), up 32 per cent compared with the 2nd quarter of 2025.

Consolidated net sales of TWYMEEG® in Japan for the 1st half of 2026 reached 5.2 billion yen (28.2 million euros1), up 34 per cent compared with the 1st half of 2025.

Sumitomo Pharma anticipates that net sales of TWYMEEG® will exceed the 10-billion-yen mark in Sumitomo Pharma’s financial year 20262. Upon reaching this milestone, POXEL will receive a contractual bonus of 1 billion yen (5.5 million euros1); the royalty rate

Poxel Appoints Yves Decadt as Chief Executive Officer to Accelerate Portfolio Development and Strategic Partnerships

Wed, 10 Jun 2026 14:13:00 -0400

LYON, France--(BUSINESS WIRE)-- Regulatory News:
Poxel (Euronext: POXEL - FR0012432516), a biopharmaceutical company listed on Euronext Paris, announces the appointment of Yves Decadt as Chief Executive Officer with effect from 10 June 2026. He succeeds Nicolas Trouche, whose role was specifically designed to support Poxel during the restructuring period that began in August 2025, with the aim of successfully developing and implementing the Continuation Plan. This transition, previously agreed to take place during the first half of 2026, is proceeding according to schedule. The Board of Directors expresses its deep gratitude to Nicolas Trouche for the exemplary commitment

Poxel Appoints Yves Decadt as Chief Executive Officer to Accelerate Portfolio Development and Strategic Partnerships

Wed, 10 Jun 2026 14:13:00 -0400

LYON, France--(BUSINESS WIRE)-- Regulatory News:
Poxel (Euronext: POXEL - FR0012432516), a biopharmaceutical company listed on Euronext Paris, announces the appointment of Yves Decadt as Chief Executive Officer with effect from 10 June 2026. He succeeds Nicolas Trouche, whose role was specifically designed to support Poxel during the restructuring period that began in August 2025, with the aim of successfully developing and implementing the Continuation Plan. This transition, previously agreed to take place during the first half of 2026, is proceeding according to schedule. The Board of Directors expresses its deep gratitude to Nicolas Trouche for the exemplary commitment

Poxel Appoints Yves Decadt as Chief Executive Officer to Accelerate Portfolio Development and Strategic Partnerships

Wed, 10 Jun 2026 14:13:00 -0400

LYON, France--(BUSINESS WIRE)-- Regulatory News:
Poxel (Euronext: POXEL - FR0012432516), a biopharmaceutical company listed on Euronext Paris, announces the appointment of Yves Decadt as Chief Executive Officer with effect from 10 June 2026. He succeeds Nicolas Trouche, whose role was specifically designed to support Poxel during the restructuring period that began in August 2025, with the aim of successfully developing and implementing the Continuation Plan. This transition, previously agreed to take place during the first half of 2026, is proceeding according to schedule. The Board of Directors expresses its deep gratitude to Nicolas Trouche for the exemplary commitment

Poxel Appoints Yves Decadt as Chief Executive Officer to Accelerate Portfolio Development and Strategic Partnerships

Wed, 10 Jun 2026 14:13:00 -0400

LYON, France--(BUSINESS WIRE)-- Regulatory News:
Poxel (Euronext: POXEL - FR0012432516), a biopharmaceutical company listed on Euronext Paris, announces the appointment of Yves Decadt as Chief Executive Officer with effect from 10 June 2026. He succeeds Nicolas Trouche, whose role was specifically designed to support Poxel during the restructuring period that began in August 2025, with the aim of successfully developing and implementing the Continuation Plan. This transition, previously agreed to take place during the first half of 2026, is proceeding according to schedule. The Board of Directors expresses its deep gratitude to Nicolas Trouche for the exemplary commitment

Poxel Appoints Yves Decadt as Chief Executive Officer to Accelerate Portfolio Development and Strategic Partnerships

Wed, 10 Jun 2026 14:13:00 -0400

LYON, France--(BUSINESS WIRE)-- Regulatory News:
Poxel (Euronext: POXEL - FR0012432516), a biopharmaceutical company listed on Euronext Paris, announces the appointment of Yves Decadt as Chief Executive Officer with effect from 10 June 2026. He succeeds Nicolas Trouche, whose role was specifically designed to support Poxel during the restructuring period that began in August 2025, with the aim of successfully developing and implementing the Continuation Plan. This transition, previously agreed to take place during the first half of 2026, is proceeding according to schedule. The Board of Directors expresses its deep gratitude to Nicolas Trouche for the exemplary commitment

Poxel Appoints Yves Decadt as Chief Executive Officer to Accelerate Portfolio Development and Strategic Partnerships

Wed, 10 Jun 2026 14:13:00 -0400

LYON, France--(BUSINESS WIRE)-- Regulatory News:
Poxel (Euronext: POXEL - FR0012432516), a biopharmaceutical company listed on Euronext Paris, announces the appointment of Yves Decadt as Chief Executive Officer with effect from 10 June 2026. He succeeds Nicolas Trouche, whose role was specifically designed to support Poxel during the restructuring period that began in August 2025, with the aim of successfully developing and implementing the Continuation Plan. This transition, previously agreed to take place during the first half of 2026, is proceeding according to schedule. The Board of Directors expresses its deep gratitude to Nicolas Trouche for the exemplary commitment

Poxel Appoints Yves Decadt as Chief Executive Officer to Accelerate Portfolio Development and Strategic Partnerships

Wed, 10 Jun 2026 14:13:00 -0400

LYON, France--(BUSINESS WIRE)-- Regulatory News:
Poxel (Euronext: POXEL - FR0012432516), a biopharmaceutical company listed on Euronext Paris, announces the appointment of Yves Decadt as Chief Executive Officer with effect from 10 June 2026. He succeeds Nicolas Trouche, whose role was specifically designed to support Poxel during the restructuring period that began in August 2025, with the aim of successfully developing and implementing the Continuation Plan. This transition, previously agreed to take place during the first half of 2026, is proceeding according to schedule. The Board of Directors expresses its deep gratitude to Nicolas Trouche for the exemplary commitment

Poxel Appoints Yves Decadt as Chief Executive Officer to Accelerate Portfolio Development and Strategic Partnerships

Wed, 10 Jun 2026 14:13:00 -0400

LYON, France--(BUSINESS WIRE)-- Regulatory News:
Poxel (Euronext: POXEL - FR0012432516), a biopharmaceutical company listed on Euronext Paris, announces the appointment of Yves Decadt as Chief Executive Officer with effect from 10 June 2026. He succeeds Nicolas Trouche, whose role was specifically designed to support Poxel during the restructuring period that began in August 2025, with the aim of successfully developing and implementing the Continuation Plan. This transition, previously agreed to take place during the first half of 2026, is proceeding according to schedule. The Board of Directors expresses its deep gratitude to Nicolas Trouche for the exemplary commitment

Poxel Appoints Yves Decadt as Chief Executive Officer to Accelerate Portfolio Development and Strategic Partnerships

Wed, 10 Jun 2026 14:13:00 -0400

LYON, France--(BUSINESS WIRE)-- Regulatory News:
Poxel (Euronext: POXEL - FR0012432516), a biopharmaceutical company listed on Euronext Paris, announces the appointment of Yves Decadt as Chief Executive Officer with effect from 10 June 2026. He succeeds Nicolas Trouche, whose role was specifically designed to support Poxel during the restructuring period that began in August 2025, with the aim of successfully developing and implementing the Continuation Plan. This transition, previously agreed to take place during the first half of 2026, is proceeding according to schedule. The Board of Directors expresses its deep gratitude to Nicolas Trouche for the exemplary commitment

Poxel Appoints Yves Decadt as Chief Executive Officer to Accelerate Portfolio Development and Strategic Partnerships

Wed, 10 Jun 2026 14:13:00 -0400

LYON, France--(BUSINESS WIRE)-- Regulatory News:
Poxel (Euronext: POXEL - FR0012432516), a biopharmaceutical company listed on Euronext Paris, announces the appointment of Yves Decadt as Chief Executive Officer with effect from 10 June 2026. He succeeds Nicolas Trouche, whose role was specifically designed to support Poxel during the restructuring period that began in August 2025, with the aim of successfully developing and implementing the Continuation Plan. This transition, previously agreed to take place during the first half of 2026, is proceeding according to schedule. The Board of Directors expresses its deep gratitude to Nicolas Trouche for the exemplary commitment

Poxel Reports First Quarter 2026 Revenue and Provides a Business Update

Wed, 20 May 2026 02:00:00 -0400

Consolidated net sales of TWYMEEG® in Japan for the first quarter of 2026 reached JPY 2.3 billion (€12.8 million 1), up 36% compared to the first quarter of 2025.

Poxel generated revenue of €1.277 million for the first quarter of 2026.

Consolidated net sales of TWYMEEG® in Japan for Sumitomo Pharma2 reached JPY 9.35 billion (€51 million), up 40% compared to the previous fiscal year.

During Sumitomo Pharma’s fiscal year 20253, Poxel received royalties of 10% on TWYMEEG® net sales

Sumitomo Pharma expects moderate double-digit growth slightly above 10% in TWYMEEG® sales for its fiscal year 20264.

Sumitomo Pharma notably expects TWYMEEG® net sales

Poxel Reports First Quarter 2026 Revenue and Provides a Business Update

Wed, 20 May 2026 02:00:00 -0400

Consolidated net sales of TWYMEEG® in Japan for the first quarter of 2026 reached JPY 2.3 billion (€12.8 million 1), up 36% compared to the first quarter of 2025.

Poxel generated revenue of €1.277 million for the first quarter of 2026.

Consolidated net sales of TWYMEEG® in Japan for Sumitomo Pharma2 reached JPY 9.35 billion (€51 million), up 40% compared to the previous fiscal year.

During Sumitomo Pharma’s fiscal year 20253, Poxel received royalties of 10% on TWYMEEG® net sales

Sumitomo Pharma expects moderate double-digit growth slightly above 10% in TWYMEEG® sales for its fiscal year 20264.

Sumitomo Pharma notably expects TWYMEEG® net sales

Poxel Reports First Quarter 2026 Revenue and Provides a Business Update

Wed, 20 May 2026 02:00:00 -0400

Consolidated net sales of TWYMEEG® in Japan for the first quarter of 2026 reached JPY 2.3 billion (€12.8 million 1), up 36% compared to the first quarter of 2025.

Poxel generated revenue of €1.277 million for the first quarter of 2026.

Consolidated net sales of TWYMEEG® in Japan for Sumitomo Pharma2 reached JPY 9.35 billion (€51 million), up 40% compared to the previous fiscal year.

During Sumitomo Pharma’s fiscal year 20253, Poxel received royalties of 10% on TWYMEEG® net sales

Sumitomo Pharma expects moderate double-digit growth slightly above 10% in TWYMEEG® sales for its fiscal year 20264.

Sumitomo Pharma notably expects TWYMEEG® net sales

Poxel Reports First Quarter 2026 Revenue and Provides a Business Update

Wed, 20 May 2026 02:00:00 -0400

Consolidated net sales of TWYMEEG® in Japan for the first quarter of 2026 reached JPY 2.3 billion (€12.8 million 1), up 36% compared to the first quarter of 2025.

Poxel generated revenue of €1.277 million for the first quarter of 2026.

Consolidated net sales of TWYMEEG® in Japan for Sumitomo Pharma2 reached JPY 9.35 billion (€51 million), up 40% compared to the previous fiscal year.

During Sumitomo Pharma’s fiscal year 20253, Poxel received royalties of 10% on TWYMEEG® net sales

Sumitomo Pharma expects moderate double-digit growth slightly above 10% in TWYMEEG® sales for its fiscal year 20264.

Sumitomo Pharma notably expects TWYMEEG® net sales

Poxel Reports First Quarter 2026 Revenue and Provides a Business Update

Wed, 20 May 2026 02:00:00 -0400

Consolidated net sales of TWYMEEG® in Japan for the first quarter of 2026 reached JPY 2.3 billion (€12.8 million 1), up 36% compared to the first quarter of 2025.

Poxel generated revenue of €1.277 million for the first quarter of 2026.

Consolidated net sales of TWYMEEG® in Japan for Sumitomo Pharma2 reached JPY 9.35 billion (€51 million), up 40% compared to the previous fiscal year.

During Sumitomo Pharma’s fiscal year 20253, Poxel received royalties of 10% on TWYMEEG® net sales

Sumitomo Pharma expects moderate double-digit growth slightly above 10% in TWYMEEG® sales for its fiscal year 20264.

Sumitomo Pharma notably expects TWYMEEG® net sales